论文部分内容阅读
Aim: Cancer immunotherapy, especially cytokine-induced killer cell therapy,has flourished in recent years.However, clinical studies about immunotherapy in combination with chemotherapy (called chemoimmunotherapy), which are still in their infancy, have not achieved a clear and definite consensus on their clinical benefits.Our aim was to investigate whether autologous cytokine-induced killer cell (CIK)immunotherapy could improve the therapeutic benefits of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC).